Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice.

Long-Term Treatment of E2HSA Increased Insulin Secretion, Reduced Plasma Glucagon Levels, and Decreased the Plasma Lipid Profile Chronic E2HSA treatment dose-dependently increased fasting plasma insulin levels in db/db mice ( Figure 5(a) ), while fasting plasma glucagon levels in E2HSA-treated groups showed an overall trend towards reduction (decreased by 28.0%, 23.7%, and 24.1% for 1 mg/kg, 3 mg/kg, and 9 mg/kg E2HSA, resp.) but with no dose-dependency ( Figure 5(c) ).

also in 4,871 other papers